期刊文献+

卵巢组织中骨桥蛋白的表达及其临床意义

原文传递
导出
摘要 目的探讨骨桥蛋白mRNA在卵巢组织中的表达及其在卵巢癌转移发生发展中的意义。方法采用RT-PCR检测46例卵巢病变组织,30例癌旁卵巢组织、18例转移淋巴结、30例卵巢良性病变及79例正常卵巢组织中骨桥蛋白mRNA的表达,并分析其与临床病理特征的关系。结果骨桥蛋白mRNA在卵巢癌组织(46/46)及癌旁卵巢组织(30/30)中表达最高,阳性率均达到100%;转移淋巴结中阳性率为83.3%(15/18);良性病变卵巢组织为53.3%(16/30);而在正常卵巢组织中表达最低,阳性率仅为27.8%(22/79),多组比较差异有统计学意义(x2=4.929,P〈0.05)。组织切片HE染色观察:镜下见卵巢癌组织与卵巢癌旁组织中颜色比较深且细胞性状不规则,转移淋巴结颜色较浅,卵巢良性病变组织与正常卵巢组织颜色最浅且细胞性状正常。结论骨桥蛋白的表达与卵巢组织恶性程度有关,并可能与卵巢癌的发生有关,因此在卵巢病变中检测其表达水平,有望作为直接的检测指标进而指导临床治疗,评判患者预后。
出处 《中国综合临床》 2013年第6期652-655,共4页 Clinical Medicine of China
  • 相关文献

参考文献16

  • 1Gostout BS, Pachman DR, Lechner R. Recognizing and treating ovarian cancer [J]. Minn Med,2012,95(3) :40-42.
  • 2Brakora KA, Lee H, Yusuf R, et al. Utility of esteopontin as a biomarker in recurrent epithelial ovarian cancer [ J]. Gynecol Oncol, 2004,93 ( 2 ) : 361-365.
  • 3Anborgh PH, Mutrie JC, Tuck AB, et al. Pre-and post-translational regulation of osteopontin in cancer [J]. J Cell Commun Signal, 2011,5(2) :111-122.
  • 4Song G, Ouyang G, Mao Y, et al. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-lalpha up-regulation and MMP9 activation [J]. J Cell Mol Med,2009,13(8B) :1706-1718.
  • 5Weber GF, Lett GS, Hanbein NC. Osteopontin is a marker for cancer aggressiveness and patient survival [ J]. Br J Cancer,2010, 103(6) :861-869.
  • 6Behera R, Kumar V, Lohite K, et al. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer ceUs [ J ]. Carcinogenesis ,2010,31 (2) :192-200.
  • 7Sung V,Gilles C, Murray A, et al. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype [ J]: Exp Cell Res ,1998,241 (2) :273-284.
  • 8Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CIM4v9 in gastric cancer [J]. Int J Cancer, 1998,79(2): 127-132.
  • 9Saitoh Y, Kuratsu J, Takeshima H, et al. Expression of osteopontin in human glioms. Its correlation with the malignancy [J]. Lab Invest, 1995,72 ( 1 ) :55-63.
  • 10Chabas D. Osteopontin, a multi-faceted molecule [J]. Med Sci(Paris) ,2005,21 (10) :832-838.

二级参考文献5

  • 1Sergio Pecorelli, Hextan YS Ngan, Neville F Hacker. Staging classifications and cfinical practice guidelines for gynaecologic cancers 2009 [EB/OL]. http : //www. figo. corn,2011-11-23.
  • 2Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. National comprehensive cancer network. NCCN clinical practice guidelines in oncology:epithelial ovarian cancer[J]. J Natl Compr Canc Netw, 2011,9( 1 ) :82-113.
  • 3Fleming GF, Ronnett BM. , Seidman J, et al. Epithelial ovarian cancer[M]// Barakat RR, Markman M, Randall M. Principles and practice of gynecologic oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins,2009:763-835.
  • 4Armstrong DK, Bundy B, Wenzel L, et al. Intraperioneal cisplatin and paclitaxel in ovarian cancer [J]. N Engl J Med,2006,354 : 34-43.
  • 5Maenpaa J. First-line bevacizumab in ovarian cancer [ J ]. Duodecim, 2011,127 ( 19 ) :2037-2044.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部